Targeting IL-11 in the treatment of BK virus-associated haemorrhagic cystitis-A promising new approach.
Laila SchneidewindThomas NeumannWilliam KrügerOliver Walther HakenbergChristian A SchmidtPublished in: Journal of cellular and molecular medicine (2020)
The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme-linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL-11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL-11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 106 copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL-11.
Keyphrases
- cell proliferation
- newly diagnosed
- stem cells
- induced apoptosis
- ejection fraction
- combination therapy
- inflammatory response
- mesenchymal stem cells
- high throughput
- high resolution
- cancer therapy
- single cell
- zika virus
- high grade
- acute respiratory distress syndrome
- patient reported outcomes
- dengue virus
- label free
- monoclonal antibody
- nuclear factor